Most drug developers working in the immunotherapy space focus on existing therapeutic targets when developing cancer drugs, optimizing ways of drugging them via engineering modalities such as CAR T-cell approaches, CRISPR editing or antibody-drug conjugates that deliver toxic payloads. The angle of one company – Cartography Biosciences – is the opposite to this. Its modus operandi is to pinpoint the immunological targets first, leveraging tools that already exist, before building therapies around them. Read More
Researchers from Adiso Therapeutics Inc. have reported the discovery of a novel small-molecule dual NLRP1 and NLRP3 inflammasome inhibitor, ADS-032, being developed for the treatment of inflammatory diseases. Screening of an in-house bioactive compound library led to the discovery of ADS-032, a sulfonylurea compound. Read More
In recent years, targeting c-Met/HGF has emerged as a relevant strategy in cancer treatment, and several compounds with this mechanism of action have reached the market. Researchers from the First Affiliated Hospital of Wenzhou Medical College and colleagues reported on the design and characterization of a novel series of 4-(4-amino phenoxy) picolinamide derivatives that led to the identification of [I] as the lead compound. Read More
Hillstream Biopharma Inc. reported a strategic reprioritization of its pipeline to focus on advancing novel oncology assets with the greatest potential and strong competitive profiles for solid tumors. Read More
Merck Sharp & Dohme Corp. has disclosed pyrazolopyrimidine derivatives acting as DNA polymerase inhibitors reported to be useful for the treatment of herpes virus infection. Read More
The protection against SARS-CoV-2 provided by spike-based vaccines, although effective, tends to decrease as the virus evolves and new variants of concern appear. Researchers from Osivax SAS reported the first results on cross-protection with OVX-033, a new human SARS-CoV-2 vaccine generated via the oligoDOM platform. Read More
Kinnate Biopharma Inc. has synthesized hepatocyte growth factor receptor (HGFR; c-Met) inhibitors reported to be useful for the treatment of cancer. Read More
Fulcrum Therapeutics Inc. has entered into a worldwide, exclusive license agreement with Camp4 Therapeutics Corp. to advance the discovery, development and commercialization of new therapeutic agents against an undisclosed target for the potential treatment of Diamond-Blackfan anemia (DBA). Read More
Beigene Co. Ltd. and Duality Biologics (Suzhou) Co. Ltd. have signed an agreement for Beigene to acquire an exclusive option for a global clinical and commercial license to a preclinical antibody-drug conjugate (ADC) therapy for select solid tumors. Read More
Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have identified monoglyceride lipase (MGLL; MAGL) inhibitors reported to be useful for the treatment of neuroinflammation, neurodegeneration, pain, cancer, diarrhea, inflammatory bowel disease, irritable bowel syndrome and psychiatric disorders. Read More
Maxcyte Inc. and Vittoria Biotherapeutics Inc. have signed a strategic platform license agreement for use of Maxcyte’s Flow Electroporation technology and Expert platform by Vittoria Biotherapeutics. Under the agreement, Vittoria will obtain nonexclusive clinical and commercial rights to use Maxcyte’s Flow Electroporation technology and Expert platform, and will pay Maxcyte platform licensing fees and program-related revenue. Read More
Aurigene Oncology Ltd. and Olema Pharmaceuticals Inc. have divulged fused benzoisoxazolyl compounds acting as histone acetyltransferase KAT6A (monocytic leukemia zinc finger protein; MOZ; MYST-3) inhibitors reported to be useful for the treatment of cancer. Read More
Haisco Pharmaceutical Group Co. Ltd. has described bromodomain-containing protein 9 (BRD9) inhibitors or BRD9 degradation inducers reported to be useful for the treatment of cancer. Read More
Researchers from Duke University presented the discovery and preclinical evaluation of [211At]YF-2, a next-generation prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical. Read More
